Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes

Objective: Because of the short potential doubling time of esophageal cancer, there is a theoretical benefit to using an accelerated radiation treatment schedule. This study evaluates outcomes and treatment-related mortality and morbidity of patients treated with neoadjuvant hyperfractionated accele...

Full description

Bibliographic Details
Main Authors: Stuart E. Samuels, MD, PhD, Matthew H. Stenmark, MD, Jae Y. Lee, MD, PhD, Jonathan B. McHugh, MD, James A. Hayman, MD, Mark B. Orringer, MD, Susan G. Urba, MD, Libin Sun, MD, Congying Xie, PhD, Feng-Ming Kong, MD, PhD, Kyle C. Cuneo, MD
Format: Article
Language:English
Published: Elsevier 2017-07-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109417300933

Internet

http://www.sciencedirect.com/science/article/pii/S2452109417300933

Similar Items